Innovating Works

filtrando por convocatoria: HORIZON-HLTH-2021-CORONA-01-02

XVR011 Phase 2: ExeVir's XVR011, a best in class nanobody-based biology that broadly neutralizes SARS-COV-1 and SARS... EXEVIR BIO tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-CORONA-01 XVR011, ExeVir's clinical lead candidate has emerged from scientific research from labs of highly regarded virologist Xavier Saelens and bio...
2021-11-15 - 2022-11-30 | Financiado
iMPact: Novel, orally available immune modulator MP1032 with anti-SARS-CoV-2 and anti-cytokine activity METRIOPHARM AG tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-CORONA-01 The current global COVID-19 pandemic has caused severe health and socio-economic challenges. Despite significant improvements in the treatme...
2021-11-16 - 2023-04-30 | Financiado
ECRAID-Prime: European Clinical Research Alliance on Infectious Diseases - PRIMary care adaptive platform trial fo... UNIVERSITAIR MEDISCH CENTRUM UTRECHT tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-CORONA-01 European citizens affected by COVID-19 have been well-served by landmark clinical trials in hospitals that have found treatments that save m...
2021-11-12 - 2024-11-30 | Financiado
EPIC-CROWN-2: Equine Polyclonal antibodies Immunotherapy against COVID-19/SARS-CoV2–VOC FABENTECH tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-CORONA-01 "The highly contagious SARS-CoV-2 virus has generated an unprecedented pandemic with global dramatic public health and socio-economic conseq...
2021-11-11 - 2023-11-30 | Financiado
EuCARE: European Cohorts of Patients and Schools to Advance Response to Epidemics EURESIST NETWORK GEIE tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-CORONA-01 The EuCARE project gathers a comprehensive multidisciplinary team of clinicians, virologists, epidemiologists, statisticians and top experts...
2021-11-15 - 2026-10-13 | Financiado
END-VOC: ENDING COVID 19 VARIANTS OF CONCERN THROUGH COHORT STUDIES: END-VOC UNIVERSITY COLLEGE LONDON tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-CORONA-01 The END-VOC consortium will support the European and global response to the COVID-19 pandemic and Variants of Concern (VOC) through well cha...
2022-08-17 - 2025-04-30 | Financiado
CoVICIS: EU-Africa Concerted Action on SAR-CoV-2 Virus Variant and Immunological Surveillance CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-CORONA-01 Despite of the successful advances achieved to date in the fight against the COVID-19 pandemic with the development of vaccines and therapy,...
2021-11-12 - 2024-10-31 | Financiado
COVend: Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stag... JOHANN WOLFGANG GOETHEUNIVERSITAET FRANKFURT AM MAIN tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-CORONA-01 More than 2.7 million hospitalisations of COVID-19-infected patients have occurred in Europe alone since the outbreak of the coronavirus in...
2021-08-01 - 2025-01-31 | Financiado
VERDI: SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics cohorts UNIVERSITA DEGLI STUDI DI PADOVA tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-CORONA-01 Variants of concern (VoC) of SARS-CoV-2 raise the possibility of increases in transmissibility, severity and immune evasion. Children and pr...
2021-11-01 - 2025-10-31 | Financiado
VERDI: SARS-coV2 variants Evaluation in pRegnancy and paeDIatrics cohorts UNIVERSITA DEGLI STUDI DI PADOVA tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-CORONA-01 Variants of concern (VoC) of SARS-CoV-2 raise the possibility of increases in transmissibility, severity and immune evasion. Children and pr...
2021-11-11 - 2025-10-31 | Financiado